IL-1RA agonist (Anakinra) in the treatment of multifocal castleman disease: Case report

Journal of Pediatric Hematology/Oncology

Volumn 30, Issue 12, 2008, Pages 920-924

  Galeotti, Caroline ^a   Tran, Tu Anh ^a   Franchi Abella, Stéphanie ^b   Fabre, Monique ^b   Pariente, Danièle ^b   Koné Paut, Isabelle ^a,b  

^a Pediatric Rheumatology   (France)

^b BICÊTRE HOSPITAL   (France)

Author keywords

Anakinra; Castleman disease; Multifocal; Pediatrics

Indexed keywords

AMOXICILLIN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GROWTH HORMONE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; VINBLASTINE; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY;

ANAMNESIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; CHILD; CLINICAL EXAMINATION; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; TONSILLITIS; TREATMENT OUTCOME; ADOLESCENT; DRUG POTENTIATION; PATHOLOGY;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRHEUMATIC AGENTS; CYCLOPHOSPHAMIDE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; TREATMENT OUTCOME; VINBLASTINE;

EID: 59149104498     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31818ab31f     Document Type: Article

References (20)

1. Parez N, Bader-Meunier B, Roy CC, et al. Paediatric Castleman disease: report of seven cases and review of the literature. Eur J Pediatr. 1999;158:631-637.
2. Smir BN, Greiner TC, Weisenburger DD. Multicentric angiofolli-cular lymph node hyperplasia in children; a clinicopathologic study of eight patients. Mod Pathol. 1996;9:1135-1142.
3. Kinney MC, Hummel DS, Villiger PM, et al. Increased interleukin-6 (IL-6) production in a young child with clinical and pathological features of multicentric Castleman's disease. J Clin Immunol. 1994; 14:382-386.
4. Hsu SU, Waldron JA, Xie SS, et al. Expression of interleukin-6 in Castleman's disease. Hum Pathol. 1993;24:833-839.
5. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood. 1989;74:1360-1367.
6. Katsume A, Saito H, Yamada Y, et al. Anti-interleukin 6 (Il-6) receptor antibody suppresses Castleman's disease like symptoms emerged in Il-6 transgenic mice. Cytokine. 2002;20:304-311.
7. Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood. 2003;102:2786-2788.
8. Larroche C, Cacoub P, Godeau P, et al. La maladie de Castleman. Rev Méd Interne. 1996;17:1003-1013.
9. Dham A, Peterson BA. Castleman disease. Curr Opin Hematol. 2007; 14:354-359.
10. Maloisel F, Andres E, Campos F, et al. Y a-t-il une place pour l' interféron-alpha dans la strategie thérapeuthique de la maladie de Castleman multicentrique? Rev Méd Int. 2000;21:435-438.
11. Baserga M, Rosin M, Schoen M, et al. Multifocal Castleman disease in pediatrics, case report. J Pediatr Hematol Oncol. 2005;27:666-669.
12. Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med. 1998; 128:657-662.
13. Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer. 2001;92:670-676.
14. Ide M, Kawachi Y, Izumi Y, et al. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol. 2006;76:119-123.
15. Casquero A, Barroso A, Fernandez Guerrero ML, et al. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol. 2006;85:185-187.
16. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627-2633.
17. Beck JT, Hsu SM, Wijdenes J, et al. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-inter-leukin-6 antibody. NEJM. 1994;330:602-605.
18. Lequerré T, Vittecoq O, Le Loet X, et al. Quelle est la place actuelle de l'IL-1Ra dans les maladies rhumatismales? Revue du Rhumatisme. 2007;74:435-439.
19. Wendling D, Jorgensen C. Traitement de la polyarthrite rhumatoïde par l' antagoniste du récepteur de l' interleukine 1. Rev Méd Interne. 2002;23:1006-1011.
20. Kötter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum. 2007;27:1081-1089.